Alnylam Pharmaceuticals Inc (ALNY)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$399.50
Buy
$405.00
$-15.08 (-3.65%)
Prices updated at 12 Dec 2025, 09:35 EST
| Prices minimum 15 mins delay
Prices in USD
Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2023 | 2024 |
|---|---|---|
| 1,828m | 2,248m | |
| 1,518m | 1,925m | |
| -282m | -177m | |
| -15.43 | -7.87 | |
| -440m | -278m | |
| -258m | -179m | |
| Sales, General and administrative | 796m | 976m |
| Interest expenses | 121m | 142m |
| Provision for income taxes | 7m | -99m |
| Operating expenses | 1,800m | 2,102m |
| Income before taxes | -434m | -377m |
| Net income available to common shareholders | -440m | -278m |
| -3.52 | -2.18 | |
| Net interest income | -26m | -20m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | -3.52 | -2.18 |
| Free cash flow per share | -0.5354 | 0.1267 |
| Book value/share | -1.3186 | 0.2502 |
| Debt equity ratio | - | 18.694282 |
Balance sheet
Year | 2023 | 2024 |
|---|---|---|
| Current assets | 2,983m | 3,295m |
| Current liabilities | 968m | 1,186m |
| Total capital | 800m | 1,092m |
| Total debt | 1,305m | 1,296m |
| Total equity | -221m | 67m |
| Total non current liabilities | - | - |
| Loans | 1,021m | 1,025m |
| Total assets | 3,830m | 4,240m |
| Total liabilities | - | - |
| Cash and cash equivalents | 813m | 966m |
| Common stock | 126m | 129m |
Cash flow
Year | 2023 | 2024 |
|---|---|---|
| Cash at beginning of period | 869m | 815m |
| Cash dividends paid | - | - |
| 42m | -43m | |
| Investments (gains) losses | -336m | -117m |
| 815m | 969m | |
| Net income | - | - |
| 104m | -8m | |
| -62m | -34m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
